Limits...
Policy and programmatic considerations for introducing a longer-acting injectable contraceptive: perspectives of stakeholders from Kenya and Rwanda.

McKenna K, Arcara J, Rademacher KH, Mackenzie C, Ngabo F, Munyambanza E, Wesson J, Tolley EE - Glob Health Sci Pract (2014)

Bottom Line: Providers appreciated the potential for a lighter workload due to fewer follow-up visits, but they were concerned that fewer visits would also decrease their ability to help women manage side effects.Manufacturing and procurement decisions could also affect cost and availability.Successful introduction of a potential longer-acting injectable may be enhanced by considering broader systemic issues, including managing cost to the health system and users, expanding access through community-based distribution, and training providers on the latest service delivery guidelines.

View Article: PubMed Central - PubMed

Affiliation: FHI 360, Durham, NC, USA kmckenna@fhi360.org.

Show MeSH
Affordability, Availability, and Adoption: Systems-Level Considerations for Enhancing Access to an LAIAbbreviations: BF, breastfeeding; CBD, community-based distribution; LAI, longer-acting injectable; TPP, target product profile.a For full version of the “Acceptability” portion of this figure, see Tolley et al, 2014.15
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4307861&req=5

f01: Affordability, Availability, and Adoption: Systems-Level Considerations for Enhancing Access to an LAIAbbreviations: BF, breastfeeding; CBD, community-based distribution; LAI, longer-acting injectable; TPP, target product profile.a For full version of the “Acceptability” portion of this figure, see Tolley et al, 2014.15

Mentions: Both international and country-level stakeholders play a pivotal role in shaping access to and demand for new contraceptive products. A representative sample of such key stakeholders identified a number of possible barriers to and opportunities for increasing access to an LAI at the policy, facility, distribution, and user population levels. Using the access “architecture” proposed by Frost and Reich,17 their insights are organized into 3 distinct components (affordability, availability, and adoption) that, when taken together, comprise the conceptual model showing foundation for access to an LAI (Figure).


Policy and programmatic considerations for introducing a longer-acting injectable contraceptive: perspectives of stakeholders from Kenya and Rwanda.

McKenna K, Arcara J, Rademacher KH, Mackenzie C, Ngabo F, Munyambanza E, Wesson J, Tolley EE - Glob Health Sci Pract (2014)

Affordability, Availability, and Adoption: Systems-Level Considerations for Enhancing Access to an LAIAbbreviations: BF, breastfeeding; CBD, community-based distribution; LAI, longer-acting injectable; TPP, target product profile.a For full version of the “Acceptability” portion of this figure, see Tolley et al, 2014.15
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4307861&req=5

f01: Affordability, Availability, and Adoption: Systems-Level Considerations for Enhancing Access to an LAIAbbreviations: BF, breastfeeding; CBD, community-based distribution; LAI, longer-acting injectable; TPP, target product profile.a For full version of the “Acceptability” portion of this figure, see Tolley et al, 2014.15
Mentions: Both international and country-level stakeholders play a pivotal role in shaping access to and demand for new contraceptive products. A representative sample of such key stakeholders identified a number of possible barriers to and opportunities for increasing access to an LAI at the policy, facility, distribution, and user population levels. Using the access “architecture” proposed by Frost and Reich,17 their insights are organized into 3 distinct components (affordability, availability, and adoption) that, when taken together, comprise the conceptual model showing foundation for access to an LAI (Figure).

Bottom Line: Providers appreciated the potential for a lighter workload due to fewer follow-up visits, but they were concerned that fewer visits would also decrease their ability to help women manage side effects.Manufacturing and procurement decisions could also affect cost and availability.Successful introduction of a potential longer-acting injectable may be enhanced by considering broader systemic issues, including managing cost to the health system and users, expanding access through community-based distribution, and training providers on the latest service delivery guidelines.

View Article: PubMed Central - PubMed

Affiliation: FHI 360, Durham, NC, USA kmckenna@fhi360.org.

Show MeSH